Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices 73091 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Parkinson’s Disease 

Biomarker Program. 

Date: December 17, 2014. 

Time: 2:30 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–435– 

6033, rajarams@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: December 3, 2014. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–28753 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR Panel: 

Cancer Health Disparities/Diversity in Basic 

Cancer Research. 

Date: December 8–9, 2014. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Rolf Jakobi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6187, 

MSC 7806, Bethesda, MD 20892, 301–495– 

1718, jakobir@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: AIDS and AIDS Related Research. 

Date: December 9, 2014. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Robert Freund, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5216, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1050, freundr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR Panel: 

Multidisciplinary Studies of HIV and Viral 

Hepatitis Co-Infection. 

Date: December 10, 2014. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Shiv A. Prasad, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5220, 

MSC 7852, Bethesda, MD 20892, 301–443– 

5779, prasads@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Fellowships: AIDS and AIDS Related 

Applications. 

Date: December 11, 2014. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Mary Clare Walker, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5208, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1165, walkermc@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 3, 2014. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–28751 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Start-Up 

Exclusive Evaluation Option License 

Agreement: A3 Adenosine Receptor 

(A3AR) Agonists as an OrallyAdministered Analgesic for Treatment 

of Chronic Neuropathic Pain 

AGENCY: National Institutes of Health, 

HHS 

ACTION: Notice 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

that the National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of a 

Start-Up Exclusive Evaluation Option 

License Agreement to BioIntervene, Inc., 

a company having a place of business in 

Saint Louis, Missouri to practice the 

inventions embodied in the following 

patent applications and patents: 

1. U.S. Patent 8,735,407, issued May 

27, 2014, titled ‘‘Purine Derivatives As 

A3 Adenosine Receptor-Selective 

Agonists’’ [HHS Ref. No. E–140–2008/0– 

US–06]; 

2. European Patent Application 

09728154.7, filed March 24, 2009, titled 

‘‘Purine Derivatives As A3 Adenosine 

Receptor-Selective Agonists’’ [HHS Ref. 

No. E–140–2008/0–EP–05]; 

3. Canadian Patent Application 

2720037, filed March 24, 2009, titled 

‘‘Purine Derivatives As A3 Adenosine 

Receptor-Selective Agonists’’ [HHS Ref. 

No. E–140–2008/0–CA–04]; 


rljohnson on DSK3VPTVN1PROD with NOTICES
73092 Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices 

4. Australian Patent 2009231978, 

issued February 20, 2014, titled ‘‘Purine 

Derivatives As A3 Adenosine ReceptorSelective Agonists’’ [HHS Ref. No. E– 

140–2008/0–AU–03]; 

5. U.S. Patent Application 13/371,081, 

filed February 10, 2012, titled ‘‘A3 

Adenosine Receptor Agonists And 

Antagonists’’ [HHS Ref. No. E–140– 

2008/1–US–01]; 

6. U.S. Provisional Application 61/ 

909,742, filed November 27, 2013, titled 

‘‘A3 Adenosine Receptor Agonists’’ 

[HHS Ref. No. E–742–2013/0–US–01]; 

and 

7. U.S. Provisional Application 62/ 

033,723, filed August 6, 2014, titled ‘‘A3 

Adenosine Receptor Agonists’’ [HHS 

Ref. No. E–210–2014/0–US–01]. 

The patent rights in these inventions 

either have been assigned to the 

Government of the United States of 

America, or have been granted exclusive 

rights to the Government of the United 

States of America. The territory of the 

prospective Start-up Exclusive 

Evaluation Option License Agreement 

may be worldwide, and the field of use 

may be limited to: ‘‘The use of an A3 

Adenosine Receptor (A3AR) agonist as 

an orally-administered analgesic, either 

as monotherapy or as an add-on 

analgesic, for treatment of chronic 

neuropathic pain conditions’’. 

Upon the expiration or termination of 

the Start-up Exclusive Evaluation 

Option License Agreement, 

BioIntervene will have the exclusive 

right to execute a Start-up Exclusive 

Patent License Agreement which will 

supersede and replace the Start-up 

Exclusive Evaluation Option License 

Agreement, with no greater field of use 

and territory than granted in the Startup Exclusive Evaluation Option License 

Agreement. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

December 24, 2014 will be considered. 

ADDRESSES: Requests for copies of the 

patents, patent applications, inquiries, 

comments, and other materials relating 

to the contemplated Start-Up Exclusive 

Evaluation Option License Agreement 

should be directed to: Betty B. Tong, 

Ph.D., Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 594–6565; Facsimile: (301) 402– 

0220; Email: tongb@mail.nih.gov. A 

signed confidentiality nondisclosure 

agreement will be required to receive 

copies of any patent applications that 

have not been published or issued by 

the United States Patent and Trademark 

Office or the World Intellectual Property 

Organization. 

SUPPLEMENTARY INFORMATION: The 

subject inventions describe selective A3 

Adenosine Receptor (A3AR) agonists, 

and their in vivo activity reducing or 

preventing development of chronic 

neuropathic pain in an animal model. 

The A3AR subtype was linked with 

helping protect the heart from ischemia, 

controlling inflammation, and 

regulating cell proliferation. The 

compounds claimed are consistently 

highly selective and have smaller 

molecular weight, thus can offer greater 

oral bioavailability. Hence, the subject 

inventions may provide a new treatment 

for chronic neuropathic pain. 

The prospective Start-up Exclusive 

Evaluation Option License Agreement 

and a subsequent Start-up Exclusive 

Patent License Agreement may be 

granted unless the NIH receives written 

evidence and argument, within fifteen 

(15) days from the date of this published 

notice, that establishes that the grant of 

the contemplated Start-up Exclusive 

Evaluation Option License Agreement 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR part 404. 

Complete applications for a license in 

the prospective field of use that are filed 

in response to this notice will be treated 

as objections to the grant of the 

contemplated Start-Up Exclusive 

Evaluation Option License Agreement. 

Comments and objections submitted in 

response to this notice will not be made 

available for public inspection and, to 

the extent permitted by law, will not be 

released under the Freedom of 

Information Act, 5 U.S.C. 552. 

Dated: December 3, 2014. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2014–28749 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Citizenship and Immigration 

Services 

[OMB Control Number 1615–0030] 

Agency Information Collection 

Activities: Application for Waiver of the 

Foreign Residence Requirement of 

Section 212(e) of the Immigration and 

Nationality Act, Form I–612; Revision 

of a Currently Approved 

ACTION: 30-Day Notice. 

SUMMARY: The Department of Homeland 

Security (DHS), U.S. Citizenship and 

Immigration Services (USCIS) will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and clearance in accordance 

with the Paperwork Reduction Act of 

1995. The information collection notice 

was previously published in the Federal 

Register on September 10, 2014, at 79 

FR 53720, allowing for a 60-day public 

comment period. USCIS did receive 1 

comment in connection with the 60-day 

notice. 

DATES: The purpose of this notice is to 

allow an additional 30 days for public 

comments. Comments are encouraged 

and will be accepted until January 8, 

2015. This process is conducted in 

accordance with 5 CFR 1320.10. 

ADDRESSES: Written comments and/or 

suggestions regarding the item(s) 

contained in this notice, especially 

regarding the estimated public burden 

and associated response time, must be 

directed to the OMB USCIS Desk Officer 

via email at oira_submission@

omb.eop.gov. Comments may also be 

submitted via fax at (202) 395–5806. All 

submissions received must include the 

agency name and the OMB Control 

Number 1615–0030. 

You may wish to consider limiting the 

amount of personal information that you 

provide in any voluntary submission 

you make. For additional information 

please read the Privacy Act notice that 

is available via the link in the footer of 

http://www.regulations.gov. 

SUPPLEMENTARY INFORMATION: 

Comments: 

Note: The address listed in this notice 

should only be used to submit 

comments concerning this information 

collection. Please do not submit 

requests for individual case status 

inquiries to this address. If you are 

seeking information about the status of 

your individual case, please check ‘‘My 

Case Status’’ online at: https://

egov.uscis.gov/cris/Dashboard.do, or 

call the USCIS National Customer 

Service Center at 1–800–375–5283. 

Written comments and suggestions 

from the public and affected agencies 

should address one or more of the 

following four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 


rljohnson on DSK3VPTVN1PROD with NOTICES